Harmony Biosciences Q1 revenue $215.4M (+17% YoY); reaffirms FY2026 guidance >$1B

Harmony Biosciences Holdings, Inc.

2026-Q1 EPS reported $0.55 revenue$215,387,000

Q1 net product revenue $215.4M, up 17% YoY; diluted EPS $0.55 vs $0.78 in Q1 2025.
Reaffirmed FY2026 WAKIX net revenue guidance of $1.0B-$1.04B; on track for >$1B.
R&D expenses $69.4M (+101%) due to $32M upfront license payments; net income declined to $32.5M.
Filed patent infringement suit vs AET Pharma/Sandoz; acquired exclusive license to pitolisant patent expiring 2042.
Appointed Peter Anastasiou COO and Glenn Reicin CFO; cash and investments $870.5M as of March 31.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Harmony Biosciences Holdings, Inc. reported the quarter ended March 31, 2026 results: revenue $215.4 million. Guidance reaffirmed.

Period: the quarter ended March 31, 2026
Revenue: $215.4 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

BIOSCIENCES REPORTS Q1 FINANCIAL RESULTS AND CONFIRMS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION; REINFORCES 2026 STRATEGIC PRIORITIES WAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion Continue to Vigorously Protect WAKIX IP into 2030; Filed Suit Against AET Pharma/Sandoz

View on SEC.gov

Browse all earnings releases →

Harmony Biosciences Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-056786

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.